prognostic signature
The company hopes that it can persuade urology practices to go with its suite of assays by covering a fuller range of treatment decision points.
Oncocyte Nets $3M VA Contract for DetermaRx Lung Cancer Prognostic Test
The test will be covered by the VA for five years to determine the risk of recurrence in early-stage lung cancer patients after surgery.
Agendia, Paige Partner to Codevelop New Assays Using MammaPrint, BluePrint Signatures
The companies aim to create new products enabling faster access to predictive information used in treatment planning for patients with breast cancer.
Tiziana Life Sciences to Spin Off StemPrintER Asset Into Separate Company
The company, which originally announced plans for a possible spin off in June, will hold a shareholder meeting to vote on the details in October.
Investigators compared expression in different men across the genes from three commercial panels, arguing that the findings highlight important unknowns.